Effect modification by catalase genotype suggests a role for oxidative stress in the association of hormone replacement therapy with postmenopausal breast cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 5, 2008, Pages 1082-1087

  Quick, Sylvia K ^a,b   Shields, Peter G ^d   Nie, Jing ^a   Platek, Mary E ^a   McCann, Susan E ^a   Hutson, Alan D ^b   Trevisan, Maurizio ^a   Vito, Dominica ^a   Modali, Ramakrishna ^e   Lehman, Teresa A ^e   Seddon, Mike ^e   Edge, Stephen B ^c   Marian, Catalin ^d   Muti, Paola ^f   Freudenheim, Jo L ^a  

^a Department of Social and Preventive Medicine ^*  (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

^e BioServe Biotechnologies Ltd   (United States)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; ESTROGEN RECEPTOR; SEX HORMONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HORMONE SUBSTITUTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT DURATION; BREAST TUMOR; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; EQUIPMENT; ESTROGEN THERAPY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATALASE; CHI-SQUARE DISTRIBUTION; EFFECT MODIFIERS (EPIDEMIOLOGY); ESTROGEN REPLACEMENT THERAPY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; OXIDATIVE STRESS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS;

EID: 52649092937     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2755     Document Type: Article

References (38)

1. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001;344:276-85.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
3. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
4. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
5. Lee SA, Ross RK, Pike MC. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer 2005;92:2049-58.
6. Tjonneland A, Christensen J, Thomsen BL, et al. Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study. Cancer 2004;100:2328-37.
7. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12.
10. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol 1996;36:203-32.
11. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV. Critical role of oxidative stress in estrogen-induced carcinogenesis. Proc Natl Acad Sci U S A 2003;100:3913-8.
12. Forsberg L, Lyrenas L, de Faire U, Morgenstern. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 2001;30:500-5.
13. Ahn J, Nowell S, McCann SE, et al. Associations between catalase phenotype and genotype: modification by epidemiologic factors. Cancer Epidemiol Biomarkers Prev 2006;15:1217-22.
14. Nadif R, Mintz M, Jedlicka A, Bertrand JP, Kleeberger SR, Kauffmann F. Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli. Free Radic Res 2005;39:1345-50.
15. Bastaki M, Huen K, Manzanillo P, et al. Genotype-activity relationship for Mn-superoxide dismutase, glutathione peroxidase 1 and catalase in humans. Pharmacogenet Genomics 2006;16:279-86.
16. Ahn J, Gammon MD, Santella RM, et al. Associations between breast cancer risk and the catalase genotype, fruit and vegetable consumption, and supplement use. Am J Epidemiol 2005;162:943-52.
17. Dabrosin C, Hammar M, Ollinger K. Impact of oestradiol and progesterone on antioxidant activity in normal human breast epithelial cells in culture. Free Radic Res 1998;28:241-9.
18. Mobley JA, Brueggemeier RW. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2004;25:3-9.
19. Liehr JG, Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med 1990;8:415-23.
20. McCann SE, Ip C, Ip MM, ety al. Dietary intake of conjugated linoleic acids and risk of premenopausal and postmenopausal breast cancer, Western New York Exposures and Breast Cancer Study (WEB Study). Cancer Epidemiol Biomarkers Prev 2004;13:1480-4.
21. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002;11:601-7.
22. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-33.
23. Ambrosone CB. Oxidants and antioxidants in breast cancer. Antioxid Redox Signal 2000;2:903-17.
24. Martin KR, Barrett JC. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum Exp Toxicol 2002;21:71-5.
25. Davies KJ. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 1999;48:41-7.
26. Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med 1996;74:297-312.
27. Cooke MS, Evans MD, Dizdaroglu M, Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 2003;17:1195-214.
28. Gago-Dominguez M, Castelao JE, Pike MC, Sevanian A, Haile RW. Role of lipid peroxidation in the epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2829-39.
29. Davies KJ. Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 1987;262:9895-901.
30. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000;27:67-73.
31. Zhang F, Chen Y, Pisha E, et al. The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone. Chem Res Toxicol 1999;12:204-13.
32. Chen Y, Shen L, Zhang F, et al. The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro. Chem Res Toxicol 1998;11:1105-11.
33. Liu X, Yao J, Pisha E, et al. Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor α. Chem Res Toxicol 2002;15:512-9.
34. Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 2000;13:342-50.
35. Daling JR, Malone KE, Doody DR, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 2003;12:1175-81.
36. Liang X, Lu B, Scott GK, Chang CH, Baldwin MA, Benz CC. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 1998;146:151-61.
37. Whittal RM, Benz CC, Scott G, Semyonov J, Burlingame AL, Baldwin MA. Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding. Biochemistry 2000;39:8406-17.
38. Webster KA, Prentice H, Bishopric NH. Oxidation of zinc finger transcription factors: physiological consequences. Antioxid Redox Signal 2001;3:535-48.